The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF.
Ten patients with CF who were more than 18 years old, participated in a double-blind, placebo-controlled study evaluating the efficacy of inhaled ipratropium bromide and metaproterenol as bronchodilators. The mean FEV1 of the group improved 17.1 percent after treatment with ipratropium bromide, 12.5 percent after metaproterenol treatment, and 16.6 percent after treatment with both of these medications together. There was no significant difference between these responses and patients who responded to one treatment tended to respond to the others. The side effects with these medications were minimal. When compared with patients in previous studies, our patients, who were much older as a group, demonstrated a greater degree of bronchodilation with ipratropium bromide and metaproterenol, as well as a greater degree of bronchoconstriction with placebo.
Weintraub
S J
SJ
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0026.
Eschenbacher
W L
WL
D000280:Administration, Inhalation; D000328:Adult; D001286:Atropine Derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009921:Metaproterenol / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation
D001286:Atropine Derivatives; D009921:Metaproterenol; D009241:Ipratropium